{{unreferenced|date=September 2016}}

{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477247048
| IUPAC_name = ''N''-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
| image = Alfuzosin.svg
| width = 275

<!--Clinical data-->
| pronounce = {{IPAc-en|æ|l|ˈ|f|juː|z|oʊ|s|ɪ|n}} {{respell|al|FEW|zoh-sin}}
| tradename = Uroxatral, others
| Drugs.com = {{drugs.com|monograph|alfuzosin-hydrochloride}}
| MedlinePlus = a64002
| pregnancy_AU = B2
| pregnancy_US = B
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = 49%
| protein_bound = 82–90%
| metabolism = [[Liver]] ([[CYP3A4]]-mediated)
| elimination_half-life = 10 hours
| excretion = [[Feces]] (69%) and [[Urine]] (24%)

<!--Identifiers-->
| IUPHAR_ligand = 7109
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 81403-80-7
| ATC_prefix = G04
| ATC_suffix = CA01
| PubChem = 2092
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00346
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2008
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 90347YTW5F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07124
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 51141
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 709

<!--Chemical data-->
| C=19 | H=27 | N=5 | O=4
| molecular_weight = 389.449 g/mol
| smiles = O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WNMJYKCGWZFFKR-UHFFFAOYSA-N
}}

'''Alfuzosin''' ([[International Nonproprietary Name|INN]], provided as the [[hydrochloride]] salt) is a [[pharmaceutical drug]] of the [[Alpha-1 blocker|α<sub>1</sub> blocker]] class. As an [[receptor antagonist|antagonist]] of the [[Alpha-1 adrenergic receptor|α<sub>1</sub> adrenergic receptor]], it works by relaxing the muscles in the [[prostate]] and [[Urinary bladder|bladder]] neck, making it easier to urinate. It is thus used to treat [[benign prostatic hyperplasia]] (BPH). 

Alfuzosin is marketed in the [[United States]] by [[Sanofi Aventis]] under the brand name '''Uroxatral''' and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural. Alfuzosin was approved by the [[Food and Drug Administration|U.S. FDA]] for treatment of BPH in June 2003.

== Side effects ==
The most common side effects are [[dizziness]] (due to [[Orthostatic hypotension|postural hypotension]]), [[upper respiratory tract infection]], [[headache]], [[Fatigue (medical)|fatigue]], and abdominal disturbances.

== Contraindications ==
Alfuzosin should be used with caution in patients with severe [[Kidney failure|renal insufficiency]], and should not be prescribed to patients with a known history of [[Long QT syndrome|QT prolongation]] who are taking medications known to prolong the [[QT interval]].

== External links ==
* [http://products.sanofi.us/uroxatral/uroxatral.html Uroxatral (alfuzosin HCl) Extended-Release Tablets Prescribing Information]
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a604002.html Alfuzosin] (General information from the [[National Institutes of Health|NIH]])

{{Drugs used in benign prostatic hypertrophy}}
{{Adrenergics}}

[[Category:Alpha blockers]]
[[Category:Carboxamides]]
[[Category:Phenol ethers]]
[[Category:Quinazolines]]
[[Category:Tetrahydrofurans]]

{{antihypertensive-stub}}
{{genito-urinary-drug-stub}}